Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 2/2012

01-02-2012 | Case Report

Clopidogrel-associated acute arthritis

Authors: Shin-ya Kawashiri, Masatake Taguchi, Atsushi Kawakami, Katsumi Eguchi

Published in: Rheumatology International | Issue 2/2012

Login to get access

Abstract

A 54-year-old Japanese man was urgently admitted to our hospital because of “unmovable” polyarthralgia, high fever and pruritus. He had taken clopidogrel 3 weeks before this admission to prevent ischemic cerebrovascular events. On the laboratory values, acute phase reactants and serum IgE were elevated. Although his symptoms had promptly improved with non-steroidal anti-inflammatory drugs (NSAIDs) and cessation of the drug, the same phenomena were re-induced by re-administration of the drug. According to the above manifestations, he was diagnosed as suffering from clopidogrel-associated acute arthritis.
Literature
1.
CAPRIE Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348:1329–1339CrossRef
2.
Chopra V, Marmur JD, Cavusoglu E (2003) The role of clopidogrel in the management of patients with ischemic heart disease. Cardiovasc Drugs Ther 17:467–477PubMedCrossRef
3.
Ringleb PA, Schellinger PD, Schwark C (2004) Clopidogrel in the management of cerebrovascular events. Int J Clin Pract 58:402–410PubMedCrossRef
4.
Garg A, Radvan J, Hopkinson N (2000) Clopidogrel associated with acute arthritis. Br Med J 320:483CrossRef
5.
Chen KK, Ginges I, Manolios N (2003) Clopidogrel-associated acute arthritis. Int Med J 33:618–619CrossRef
6.
Boulman N, Rozenbaum M, Slobodin G, Rosner I (2005) Acute polyarthritis associated with clopidogrel treatment. Isr Med Assoc J 7:670–671PubMed
7.
Tayyareci Y (2008) Acute arthritis associated with loading dose of clopidogrel. J Clin Rheumatol 14:254–255PubMedCrossRef
8.
Blauwet L, Matteson E (2003) Acute inflammatory arthritis: an adverse effect of clopidogrel? J Clin Rheumatol 9:128–129PubMedCrossRef
Metadata
Title
Clopidogrel-associated acute arthritis
Authors
Shin-ya Kawashiri
Masatake Taguchi
Atsushi Kawakami
Katsumi Eguchi
Publication date
01-02-2012
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 2/2012
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-009-1267-y

Other articles of this Issue 2/2012

Rheumatology International 2/2012 Go to the issue

Original Article

Relationship between diagnosis delay and disease features in Moroccan patients with ankylosing spondylitis

Original Article

A proposal of simple calculation (ERI calculator) to predict the early response to TNF-α blockers therapy in rheumatoid arthritis

Short Communication

The expression of RANKL and OPG in the various grades of osteoarthritic cartilage

Review

Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations

Original Article

Diaphragmatic movements in ankylosing spondylitis patients and their association with clinical factors: an ultrasonographic study

Erratum

Erratum to: MicroRNA array analysis of microRNAs related to systemic scleroderma
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits